Physician profile
Baleigh Morgan Swaney
NPI 1215556311
$2,566.13
in general payments reported to CMS, 2019-2025
24 companies · $1,719 in 2025
The $1,719 reported for 2025 was more than what 97% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $24.20 · 2024: $822 · 2025: $1,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,541.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $498.24 | 2024-2025 | |
| Novo Nordisk INC | $316.13 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Ardelyx, INC. | $236.87 | 2024-2025 | Ibsrela |
| Amgen INC. | $148.75 | 2024-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $134.71 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $111.11 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $109.14 | 2024-2025 | Breztri, Farxiga |
| Corium, LLC | $105.28 | 2024-2025 | Azstarys |
| Sumitomo Pharma America, INC. | $104.86 | 2024-2025 | Gemtesa |
| Neurocrine Biosciences, INC. | $97.24 | 2024-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $95.79 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $84.75 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $80.93 | 2024-2025 | Trintellix |
| Antares Pharma, INC. | $74.80 | 2024-2025 | Xyosted |
| Lundbeck LLC | $55.87 | 2025 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.00 | 2024-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $48.30 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $39.30 | 2025 | |
| Lilly USA, LLC | $38.24 | 2024 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $33.48 | 2024-2025 | Cologuard Collection Kit |
| Atland Pharmaceuticals, LLC | $30.25 | 2024 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Shield Therapeutics INC | $27.92 | 2025 | |
| Btg International INC. | $24.20 | 2022 | |
| Medtronic, INC. | $19.97 | 2025 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baleigh Swaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.